Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Rating of “Moderate Buy” by Brokerages

Generate Biomedicines Inc (NASDAQ:GENB) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $25.40.

Several analysts recently commented on GENB shares. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating for the company. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price for the company. Piper Sandler initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. Finally, Morgan Stanley boosted their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th.

Generate Biomedicines Stock Performance

GENB opened at $16.50 on Thursday. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $18.18. The stock’s 50 day moving average price is $14.02. The firm has a market capitalization of $2.12 billion and a price-to-earnings ratio of -15.42.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.